TY - JOUR
T1 - Durvalumab, tremelimumab, and platinum chemotherapy in EGFR mutation-positive NSCLC
T2 - an open-label phase 2 trial (ILLUMINATE)
AU - Lee, Chee Khoon
AU - Liao, Bin Chi
AU - Subramaniam, Shalini
AU - Chiu, Chao Hua
AU - Mersiades, Antony J.
AU - Ho, Chao Chi
AU - Brown, Chris
AU - Lai, Chun Liang
AU - Hughes, Brett G.M.
AU - Yang, Tsung Ying
AU - O'Byrne, Ken
AU - Luo, Yung Hung
AU - Yip, Sonia
AU - Ho, Ching Liang
AU - Bray, Victoria
AU - Su, Wu Chou
AU - Moore, Melissa
AU - Feng, Wei Lien
AU - Bai, Ya Ying
AU - Ford, Kate
AU - Cummins, Michelle M.
AU - Stockler, Martin R.
AU - Solomon, Benjamin J.
AU - John, Thomas
AU - Chih-Hsin Yang, James
PY - 2025/2
Y1 - 2025/2
N2 - Introduction: EGFR-mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab, and platinum-pemetrexed in EGFR-mutant NSCLC after progression with EGFR tyrosine kinase inhibitors (TKIs). Methods: Participants were treated with induction durvalumab, tremelimumab, and platinum-pemetrexed, followed by durvalumab-pemetrexed maintenance. Participants were divided into two cohorts: (1) EGFR exon 20 T790M negative (T790M−, progressing on either first-line osimertinib, or on a single line of first/second generation TKI), and (2) T790M positive (T790M+, progressing on greater than or equal to 1 lines of TKI, including osimertinib). The primary endpoint was the confirmed objective response rate (ORR) assessed by the investigators. Progression-free survival and safety were secondary outcomes. Results: One hundred participants from Australia and Taiwan were enrolled. Median follow-up was 26 months with 88% and 96% experiencing progression events for T790M− and T790M+, respectively. The ORR for T790M− was 31% (95% confidence interval: 20-45), including two complete responses. The ORR for T790M+ was 21% (95% confidence interval: 12-34). Median durations of response were 9.5 months and 6.3 months for T790M− and T790M+, respectively; median progression-free survival rates were 6.5 months and 4.9 months, respectively. For T790M−, ORR was 27% for 50% or higher PD-L1 (n = 22) and 0% for less than 50% PD-L1 (n = 10), respectively. For T790M+, ORR was 17% for 50% or higher PD-L1 (n = 24). The safety profile was consistent with previous reports. Conclusions: Durvalumab, tremelimumab, and platinum-pemetrexed had modest anti-tumor activity in EGFR-mutant NSCLC after progression on TKI. The T790M− cohort had higher ORR and a longer duration of response. Immune adverse events were not increased with tremelimumab. The clinical registration number of this trial is NCT03994393.
AB - Introduction: EGFR-mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab, and platinum-pemetrexed in EGFR-mutant NSCLC after progression with EGFR tyrosine kinase inhibitors (TKIs). Methods: Participants were treated with induction durvalumab, tremelimumab, and platinum-pemetrexed, followed by durvalumab-pemetrexed maintenance. Participants were divided into two cohorts: (1) EGFR exon 20 T790M negative (T790M−, progressing on either first-line osimertinib, or on a single line of first/second generation TKI), and (2) T790M positive (T790M+, progressing on greater than or equal to 1 lines of TKI, including osimertinib). The primary endpoint was the confirmed objective response rate (ORR) assessed by the investigators. Progression-free survival and safety were secondary outcomes. Results: One hundred participants from Australia and Taiwan were enrolled. Median follow-up was 26 months with 88% and 96% experiencing progression events for T790M− and T790M+, respectively. The ORR for T790M− was 31% (95% confidence interval: 20-45), including two complete responses. The ORR for T790M+ was 21% (95% confidence interval: 12-34). Median durations of response were 9.5 months and 6.3 months for T790M− and T790M+, respectively; median progression-free survival rates were 6.5 months and 4.9 months, respectively. For T790M−, ORR was 27% for 50% or higher PD-L1 (n = 22) and 0% for less than 50% PD-L1 (n = 10), respectively. For T790M+, ORR was 17% for 50% or higher PD-L1 (n = 24). The safety profile was consistent with previous reports. Conclusions: Durvalumab, tremelimumab, and platinum-pemetrexed had modest anti-tumor activity in EGFR-mutant NSCLC after progression on TKI. The T790M− cohort had higher ORR and a longer duration of response. Immune adverse events were not increased with tremelimumab. The clinical registration number of this trial is NCT03994393.
KW - Checkpoint inhibitors
KW - Chemotherapy
KW - EGFR mutation
KW - Non-small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85214336454&partnerID=8YFLogxK
U2 - 10.1016/j.jtocrr.2024.100771
DO - 10.1016/j.jtocrr.2024.100771
M3 - Article
AN - SCOPUS:85214336454
SN - 2666-3643
VL - 6
JO - JTO Clinical and Research Reports
JF - JTO Clinical and Research Reports
IS - 2
M1 - 100771
ER -